- Research works
- 78 ▲ 180% vs 2013–17
- Citations
- 1.1k 14.6 per fractional work
- Top-10% rate
- 19.6% record average 16.5%
- Open access
- 49% world 28%
Not ranked overall: C4 Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.9×. Every wedge is a field page.
- Immunology and Microbiology 8.9×
- Biochemistry, Genetics and Molecular Biology 7.5×
- Medicine 2.2×
- Neuroscience 1.5×
- Materials Science 0.8×
- Chemical Engineering 0.7×
- Mathematics 0.7×
- Chemistry 0.6×
- Nursing 0.5×
- Pharmacology, Toxicology and Pharmaceutics 0.2×
- Agricultural and Biological Sciences 0.1×
- Business, Management and Accounting 0.1×
- Environmental Science 0.1×
- Social Sciences 0.0×
- Engineering 0.0×
Which keywords describe research at C4 Therapeutics (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Therapy, Cancer, Tumor Microenvironment, Proteasome Inhibitors, Transcriptional Regulation, Cancer Immunotherapy, Innate Immunity and BET Bromodomains.
- Tumor Antigen
- Mutation
- Hematopoietic Stem Cells
- Dendritic Cells
- RNA methylation
- Minimal Residual Disease
- Diagnosis Criteria
- Therapeutic Antibodies
- Genomic Analysis
- Immune Response
- Cancer Progression
- Lymphoma
- Immune Checkpoint Blockade
- Proteasome
- Tumor Regression
- Immunotherapy
- Innate Immunity
- Transcriptional Regulation
- Inflammation
- Cancer
- Cancer Therapy
- Tumor Microenvironment
- Proteasome Inhibitors
- Cancer Immunotherapy
- BET Bromodomains
- PROTACs
- Gene Therapy
- Ubiquitin
- PD-1 and PD-L1
- CAR T Cells
- Chimeric Antigen Receptor
- Immunity
- Fc Receptors
- Antigen Presentation
- International Myeloma Working Group
- Neurodegeneration
- m6A-seq
- Drug Discovery
- IL-6
- STAT3
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer Therapy5▲ 19×11 topics
- Cancer5▲ 8.0×14 topics
- Tumor Microenvironment4▲ 22×7 topics
- Inflammation3▲ 3.7×10 topics
- Proteasome Inhibitors3▲ 109×2 topics
- Transcriptional Regulation3▲ 42×5 topics
- Cancer Immunotherapy3▲ 42×2 topics
- Innate Immunity3▲ 19×5 topics
- BET Bromodomains2▲ 204×1 topic
- Immunotherapy2▲ 8.1×5 topics
- PROTACs2▲ 204×1 topic
- Tumor Regression2▲ 51×2 topics
- Gene Therapy2▲ 25×3 topics
- Proteasome2▲ 139×1 topic
- Ubiquitin2▲ 139×1 topic
- Immune Checkpoint Blockade2▲ 41×1 topic
- PD-1 and PD-L12▲ 41×1 topic
- Lymphoma2▲ 26×2 topics
- CAR T Cells2▲ 55×1 topic
- Cancer Progression2▲ 22×4 topics
- Chimeric Antigen Receptor2▲ 55×1 topic
- Immune Response2▲ 6.9×4 topics
- Immunity2▲ 9.1×5 topics
- Genomic Analysis1▲ 13×3 topics
- Fc Receptors1▲ 56×1 topic
- Therapeutic Antibodies1▲ 44×1 topic
- Antigen Presentation1▲ 32×2 topics
- Diagnosis Criteria1▲ 79×1 topic
- International Myeloma Working Group1▲ 79×1 topic
- Minimal Residual Disease1▲ 42×2 topics
- Neurodegeneration1▲ 9.2×6 topics
- RNA methylation1▲ 31×1 topic
- m6A-seq1▲ 31×1 topic
- Dendritic Cells1▲ 27×1 topic
- Drug Discovery1▲ 11×5 topics
- Hematopoietic Stem Cells1▲ 29×3 topics
- IL-61▲ 119×1 topic
- Mutation1▲ 14×5 topics
- STAT31▲ 119×1 topic
- Tumor Antigen1▲ 40×1 topic
Which research topics does C4 Therapeutics (United States) publish most on?
By volume in 2022–2025: Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, Cancer Immunotherapy and Biomarkers and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Protein Degradation and Inhibitors Molecular Biology 2 works
- 2 Ubiquitin and proteasome pathways Molecular Biology 2 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 4 CAR-T cell therapy research Oncology 2 works
- 5 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 6 RNA modifications and cancer Molecular Biology 1 works
- 7 Multiple Myeloma Research and Treatments Hematology 1 works
- 8 Immunotherapy and Immune Responses Immunology 1 works
- 9 Cytokine Signaling Pathways and Interactions Oncology 1 works
- 10 Traditional Chinese Medicine Studies Complementary and alternative medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has C4 Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 180% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Watertown
- Boston Biomedical Research Institute
- Primary Source
- Cambridge Scientific (United States)
- Radiation Monitoring Devices (United States)
- Arsenal Medical (United States)
- Pathfinder International
- New England Research Institutes
- Perkins School for Blind
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.